Purpose: The relationship between the excision repair cross-complementing 1 (ERCC1) rs11615 polymorphism (C/T) and responses to oxaliplatin-based chemotherapy for gastric cancer (GC) and colorectal cancer (CRC) patients is controversial. Therefore, we performed a meta-analysis to assess this relationship.
Method: Relevant studies were retrieved by searching the PubMed database. A systematic review and meta-analysis was performed to evaluate the predictive value of the ERCC1 rs11615 polymorphism for the clinical outcomes of GC and CRC patients receiving oxaliplatin-based chemotherapy. Therapeutic response to chemotherapy, progression-free survival (PFS), and overall survival (OS) were analyzed.
Results: A total of 22 studies were included in this meta-analysis, including 1,242 cases of GC and 1,772 cases of CRC. For the ERCC1 rs11615 polymorphism, the T allele was associated with a reduced response to chemotherapy in Asians and GC patients (P<0.05). On the other hand, the T allele was associated with a significant increase in the risk for shorter PFS and OS in all patients (PFS: hazard ratio [HR] =1.22, P<0.001, 95% confidence interval [CI] =0.93-1.51 and OS: HR =1.12, P<0.001, 95% CI =0.85-1.40).
Conclusion: The ERCC1 rs11615 polymorphism was closely associated with the clinical outcomes of GC and CRC patients treated with oxaliplatin-based chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365759 | PMC |
| http://dx.doi.org/10.2147/OTT.S80913 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic signatures of and expression, along with SNPs variants, unveil favorable prognosis in SCLC patients undergoing platinum-based chemotherapy.
Oncol Res
December 2024
Clinical Oncology Unit, Careggi University Hospital, Florence, 50134, Italy.
Background: Platinum chemotherapy (CT) remains the backbone of systemic therapy for patients with small-cell lung cancer (SCLC). The nucleotide excision repair (NER) pathway plays a central role in the repair of the DNA damage exerted by platinum agents. Alteration in this repair mechanism may affect patients' survival.
View Article and Find Full Text PDFAssociation of Gene Polymorphisms (rs3212986 and rs11615) With the Risk of Lung Cancer in a Population From Southeast Iran.
J Res Health Sci
September 2024
Cardiovascular Research Center, Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.
Article Synopsis
- - The study investigates the relationship between specific genetic variations (SNPs rs3212986 and rs11615) in the excision repair cross-complementation group 1 (ERCC1) gene and non-small cell lung cancer (NSCLC) in patients compared to healthy individuals.
- - Results reveal that the TT genotype of rs11615 and the AA genotype of rs3212986 are linked to an increased risk of developing NSCLC, with notable odds ratios indicating significance.
- - Additionally, a strong connection was found between smoking and lung cancer risk, while no significant relation was identified between SNP genotypes and sensitivity to common lung cancer treatments, cisplatin and carboplatin.
and Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer.
Pharmaceutics
August 2024
Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Article Synopsis
- Standard first-line chemotherapy for small cell lung cancer (SCLC) combines platinum and etoposide, but while effective, it has limitations like non-durable responses and toxicity.
- Genetic variants in DNA-repair and etoposide metabolism genes were studied in 145 SCLC patients to predict treatment outcomes and safety, with findings linking certain genetic variants to better progression-free survival (PFS).
- The study shows potential markers, like the rs11615 variant, could help personalize treatment, especially in limited-stage SCLC, but more research is needed to confirm these results.
Genetic polymorphisms and platinum-induced hematological toxicity: a systematic review.
Front Pharmacol
August 2024
Hunan Provincial Maternal and Child Health Care Hospital, Changsha, China.
Article Synopsis
- Platinum-based chemotherapy can cause severe blood-related side effects, leading to dose changes or stop of the treatment, with genetic differences potentially affecting these risks.
- This systematic review analyzed studies linking genetic variants to platinum-induced blood toxicity, examining relevant research databases for papers published until January 2022.
- Out of 83 studies reviewed, the findings were mixed due to various issues, but certain genetic markers (SNPs) showed promise and warrant further investigation in more rigorous studies.
Potential association of and variant alleles with increased risk for palbociclib toxicity.
Pharmacogenomics
September 2024
Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
This study evaluated associations between and variants in other pharmacogenes (, , , , ) and the risk for palbociclib-associated toxicities. Two hundred cancer patients who received standard-of-care palbociclib were genotyped and associations with toxicity were evaluated retrospectively. No significant associations were found for , , _rs1045642, _rs2231142, _rs3212986 and _rs11615.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!